On topic Re: licensing/partnerships. I’m looking

On topic Re: licensing/partnerships. I’m looking for a handle on licensing potential to think more clearly about what may be possible as company mgmt, with its newly added licensing leadership, goes about its redirecting.

While it’s not a correlated comparison to what NASH could generate, I point to an example of Jazz Pharma/Werewolf where Werewolf presented at a conference and shortly thereafter Jazz struck a deal for a preclinical drug, WTX-613, developed by Werewolf. $15 million upfront with Werewolf eligible for development, regulatory, commercial payments up to $1.26 billion. Werewolf will receive tiered, mid-single digit royalties pending approval.

I wonder if anyone has a considered projection of partnership funding for agreement-worthy NASH Phase 2 results that would be meaningful to aid a build out of partnerships for a potential platform drug like Leronlimab.

What up front? What scope of eligible payments? What royalty percentage that would be between this mid-single digit example and the fifty percent tied to the Vyera/Regnum HIV agreement? What would you adjust in a royalty proposal that would produce more capital now to shore up current financials?

Add any other development agreement examples to the thread if it will help fine tune projection ideas.

We’ve all had ideas about what could come out during investor calls on this question and it would be helpful to all longs to have a sense from the board of what to look for once phase results are released.